slide1 l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
an NIH IP/CP for Topical Microbicides PowerPoint Presentation
Download Presentation
an NIH IP/CP for Topical Microbicides

Loading in 2 Seconds...

play fullscreen
1 / 17

an NIH IP/CP for Topical Microbicides - PowerPoint PPT Presentation


  • 231 Views
  • Uploaded on

A PHASE 1 SAFETY AND ACCEPTABILITY STUDY OF THE UC-781 MICROBICIDE GEL APPLIED RECTALLY IN HIV SERONEGATIVE ADULTS: AN INTERIM SAFETY REPORT AT 50% COMPLETION. P Anton, T Saunders, A Adler, C Siboliban, E Khanukhova, C Price,

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'an NIH IP/CP for Topical Microbicides' - paul


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

A PHASE 1 SAFETY AND ACCEPTABILITY STUDY OF THE UC-781 MICROBICIDE GEL APPLIED RECTALLY

IN HIV SERONEGATIVE ADULTS:

AN INTERIM SAFETY REPORT

AT 50% COMPLETION

P Anton, T Saunders, A Adler, C Siboliban, E Khanukhova, C Price,

J Elliott, K Tanner, D Cho, EJ Johnson, J Klein, A Dominquez, S Watson,

Ana Ventuneac,Alex Carballo-Dieguez, J Boscardin, Y Zhao, AM Corner, C Mauck,

I McGowan

UCLA, NIH, CONRAD

an NIH IP/CP for Topical Microbicides

slide2

Relevant Clinical Context

  • Any microbicides demonstrating efficacy in vaginal trials will likely require demonstration of rectal safety
  • Receptive anal intercourse (RAI) is main risk for MSM but also significant contribution to heterosexual transmission
  • By numbers alone, more RAI in heterosexuals; not well quantified in higher risk settings
  • Rectosigmoid: Increased vulnerability/risk per sexual act
  • Rectal compartment very different than cervicovaginal
  • The first rectally-focused NIH IP/CP microbicide effort
  • Longer goal: development of an acceptable, effective, affordable, rectally-formulated microbicide

NIH IP/CP

slide3

Epithelia

Compartment Difference: Rectum

NIH IP/CP

slide4

1st Rectal Microbicide IND Trial

  • interim, blinded analysis at 50% completion of safety data only
  • next 2 presentations report on blinded interim data analyses
  • Sponsored by Biosyn, now CONRAD with NIAID’s U19 IP/CP
  • Single site: UCLA
  • NNRTI: UC-781 evaluated in 36 seronegatives (men & women)
  • 3 Groups: 0.1% gel vs. 0.25% gel vs. placebo gel (Universal, not excipient; same as vaginal trials)
  • Single and 7d exposures (subset enrolled in 24 hour pK)
  • Using: vaginal formulation of the reverse-transcriptase inhibitor
  • UC-781 gel applied rectally with vaginal applicator

NIH IP/CP

slide5

Applicator (vaginal form)

  • Participants apply small amount of lubricant to applicator for insertion.
  • Not to use OTC lubricants as they may cause toxicity and interact with the study product.

NIH IP/CP

slide6

Trial Objectives and Indices

  • Primary Objective:
  • To evaluate the safety and acceptability of 0.1% and 0.25% UC-781 vaginal microbicide gel versus placebo when applied rectally.
  • Indices:
    • Frequency of ≥Grade 2 adverse events
    • Acceptability assessments

NIH IP/CP

slide7

Trial Objectives and Indices

  • Secondary Objectives: Using very detailed, sensitive assays, to determine whether use is associated with rectal mucosal damage (immunotox):
      • Epithelial sloughing
      • Histopathology
      • Mucosal mononuclear cell phenotype (flow)
      • Mucosal cytokine mRNA (tissue)
      • Mucosal cytokines (secreted)
      • Mucosal immunoglobulins
      • Fecal calprotectin
      • Explants- ex vivo susceptibility to HIV infection

*(Many compared to baselines established in HPTN 056..McGowan JAIDS 2007)

NIH IP/CP

slide8

NEW: Amended Toxicity Tables for AE (1° endpoint)

  • DAIDS EAE Reporting Manual and DAIDS Toxicity Tables
  • Clarifications/Additions to avoid inaccurate AE reporting:

“diarrhea”

“hematochezia” (from NCI, not in DAIDS)

“bloody diarrhea”

“Proctitis” (stricter definition than DAIDS; used by NIDDK)

“bruising” (to cover AE related to applicator injury)(NCI)

  • Protocol team to review q 2-4 weeks; DSMB on call
  • Trial suspended if 2 or more subjects have ≥ Grade 3

NIH IP/CP

slide9

Study Outline

  • Study Population: HIV negative men and women with a history of RAI (in order to give context to applicator use and acceptability assessments)
  • Study Size: 36 participants (men and women) in 3 arms
  • Accrual: 9-12 months
  • Duration: 18 months (last subject already enrolled; completion date for entire study: mid 3/08)

NIH IP/CP

inclusion criteria
Inclusion Criteria

Men who meet the following 10 criteria and women who meet the following 12 criteria are eligible for inclusion in the study:

1. Age of 18

2.HIV-1 status antibody negative as documented at screening

3.Understands and agrees to local STI reporting requirements

4.Able and willing to communicate in English

5.Able and willing to provide written informed consent to take part in the study

6.Able and willing to provide adequate information for locator purposes

7.Availability to return for all study visits, barring unforeseen circumstances

8.A history of consensual RAI at least once in lifetime*

*Required to assure that subjects have a context for the acceptability assessments.

9.Willing to abstain from insertion of anything per rectum other than the study gel for the 1 week prior to treatment, 1 week prior each flexible sigmoidoscopy (i.e. during week of study gel use), and 1 week after each flexible sigmoidoscopy.

10.Willing to use condoms for the duration of the study

In addition to the criteria listed above, female participants must meet the following criteria:

11.Negative pregnancy test

12.Post-menopausal or using an acceptable form of contraception.

exclusion criteria
Exclusion Criteria

1.HIV positive at baseline

2.History of inflammatory bowel disease

3.Active inflammatory condition of the GI tract at baseline

4.Active rectal infection at baseline

5.≥Grade 2 laboratory abnormality at baseline

6.Allergy to methylparaben, propylparaben, sorbic acid

7.History of alcoholism or IV drug abuse

8.Unwillingness to refrain from chronic use of aspirin and NSAIDs.

9.Use of warfarin or heparin

10.Use of systemic immunomodulatory medications within 4 weeks of Visit 2

11.Use of rectally administered medications, with the exception of over the counter enemas, within 4 weeks of Visit 2

12.Use of product containing nonoxynol-9 rectally within 4 weeks of Visit 2

13.Use of any investigational products within 4 weeks of Visit 2

14.Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study.

In addition to the criteria listed above, female participants will be excluded if they meet any of the following criteria:

15.Pregnancy

16.Breastfeeding

17. Female of child-bearing potential unwilling to use acceptable form of contraception

slide12

Randomization: 0.1% UC-781, 0.25% UC-781, or placebo

 1 wk

 1 wk

<4 wk

flex

flex

flex

Week 0

Week 2

Week 5

Week 6

Week 8

~ 8 days

Visit 1

Visit 2

Visit 3

Visit 4

Visit 5

Visit 6

Safety;

Given

7 daily

doses

Screening

7-day

exam

Phone

interview

Single-dose

exam

Baseline

Baseline Behav Questionnaire

In depth tel interview

Acceptability

questionnaire

RM Phase 1 Trial Design

NIH IP/CP

slide13

‘post-biopsy’ appearance

UCLA IRB # 02-05-001;

approved for 30 bx per visit

slide14

Clinical Results at 50% Completion: Blinded

  • Recruit/Enroll: CFAR/IPCP Trial Registry has helped.
      • 92 volunteers
      • 36 screened
      • 22 enrolled (entered V2)
      • 19 completed
      • 13 men (72%) and 5 women (28%)
      • no withdrawals (including due to procedures)
      • average of 80 phone calls/emails to get each subject recruited and through trial

NIH IP/CP

slide15

Clinical Results at 50% Completion: Blinded

  • Adverse events:
      • No Grade 3 or 4 AE
      • 64 total AE reported:
        • 7 Grade 2 AE (in 4 of 19 subjects completing)
          • 4/7 from 1 individual at V3 (fever, cramps, flatulence, diarrhea; none on 7 day exposure): “possibly related”
          • 2 with limited diarrhea (resolved): “possibly related”
          • 1 transient thrombocytopenia: “not related”
      • NO procedure related AE

NIH IP/CP

slide16

Conclusions at 50% completion

  • Appears safe and well-tolerated
  • Subjects highly compliant with demanding protocol
  • Procedures well tolerated
  • No Drop outs/withdrawals
  • No Grade 3 or 4 AE
  • No procedure related AE
  • 7 Grade 2 AE reported in 4 of 19 individuals completing (4 from one individual at V3; not at V5)
  • New NIAID RM toxicity tables are useful in clinical trials where biopsy procedures produce findings (blood, diarrhea, urgency) that otherwise would have been reported as AE, “possibly-related’ to product.

NB: Findings not much different at 75% completion

NIH IP/CP

slide17

NIH NIAID U19 IP/CP #AI060614: “Microbicide Development Program”

UCLA

Ian McGowan (U Pitt)

Chomchay Siboliban

Amy Adler

Terry Saunders

Elena Khanukhova

Charlie Price

Julie Elliott

John Boscardin

Ying Zhao

Daniel Cho

Karen Andrews

Elizabeth Johnson

Alexis Dominguez

Julia Klein

Biosyn, Inc

Anne Marie Corner

Linda Knapp

Linda Kristekas

NIH

Jim Turpin

Jeanna Piper

Cherylnn Mathias

Grace Chow

CONRAD

Henry Gabelnick

Christine Mauck

Tim McCormick

Marianne Callahan

Consultants

Alex Carballo-Dieguez

Ana Vetuneac

VOLUNTEERS!

an NIH IP/CP for Topical Microbicides